Fresenius Kabi has sold its German subsidiary CFL to NewCo Pharma, for an undisclosed sum.
Both companies specialise in IV oncology drug compounding, i.e preparing personalised medicines for patients by mixing individual ingredients together in the exact strength and dosage required.
Fresenius says it will remain active in compounding, but in Germany the focus will be on parenteral nutrition products, “an area that offers attractive growth opportunities”.
